Cargando…
P2 3-year observation study of Plerixafor use in New Zealand
INTRODUCTION: Plerixafor, a novel CXCR4 pathway antagonist, is used to mobilise CD34-positive stem cells for autologous stem cell transplantation to treat haematological malignancy. Data regarding the rates of failure to mobilise and frequency of use of Plerixafor vary widely. METHODS: This retrospe...
Autores principales: | Swinn, Tim, Butler, Andrew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8030232/ http://dx.doi.org/10.1093/bjsopen/zrab032.001 |
Ejemplares similares
-
P112: Hand hygiene practice in new zealand hospitals one year into the hand hygiene New Zealand programme
por: Freeman, JT, et al.
Publicado: (2013) -
P1343: TRANSPLANT OUTCOMES OF LYMPHOMA PATIENTS UNDERGOING STEM CELL MOBILIZATION WITH PLERIXAFOR
por: Gunes, A. K., et al.
Publicado: (2022) -
Plerixafor
por: Slater, Susan
Publicado: (2012) -
Incidence and characteristics of vitamin D deficiency rickets in New Zealand children: a prospective New Zealand paediatric surveillance unit study
por: Wheeler, Benjamin, et al.
Publicado: (2015) -
P04.81. Mapping the natural health landscape: New Zealand-based CAM professionals survey
por: Vempati, R, et al.
Publicado: (2012)